Scinai Immunotherapeutics (SCNI) Corporate Presentation summary

Leadership and expertise

• Executive team includes experienced leaders from GSK, Novartis, Merck, and NeuroDerm, with deep backgrounds in pharma R&D, manufacturing, and supply chain management.

• Board and scientific advisors feature industry veterans and academic leaders from Max Planck, UMG, Bristol Myers Squibb, and Bausch Health.

NanoAb platform and technology

• Proprietary NanoAb platform leverages alpaca-derived single-domain antibodies for broad therapeutic applications, especially in inflammation and immunology.

• NanoAbs offer advantages over traditional mAbs, including higher API yield, faster and cheaper yeast-based production, superior specificity, and improved patient convenience.

• Collaboration with Max Planck and UMG provides access to world-class science, patents, and initial NanoAb characterization.

Pipeline and clinical development

• Lead asset is an anti-IL-17 NanoAb for psoriasis, with in vivo proof-of-concept completed and first-in-human trial planned for 2026.

• Pipeline includes candidates for psoriasis, psoriatic arthritis, asthma, atopic dermatitis, wet AMD, and rare skin diseases.

• Anti-IL-17 NanoAb demonstrated superior neutralization of IL-17A, F, and AF compared to leading biologics in preclinical studies.

• Local administration via pen injector targets mild to moderate psoriasis, addressing unmet needs for localized, less frequent, and safer treatments.